10x Genomics (NASDAQ:TXG) Insider Benjamin Hindson Sells 11,595 Shares of Stock

Posted by Francis Steltz on May 28th, 2026

10x Genomics (NASDAQ:TXG – Get Free Report) insider Benjamin Hindson sold 11,595 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total transaction of $283,381.80. Following the transaction, the insider owned 502,000 shares of the company’s stock, valued at $12,268,880. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

10x Genomics Trading Up 3.6%

10x Genomics stock opened at $25.51 on Thursday. The stock has a market cap of $3.24 billion, a P/E ratio of -150.06 and a beta of 2.05. The company has a fifty day simple moving average of $22.03 and a 200-day simple moving average of $19.89. 10x Genomics has a 12-month low of $8.41 and a 12-month high of $26.44.

10x Genomics (NASDAQ:TXG – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.19. The business had revenue of $150.84 million during the quarter, compared to analysts’ expectations of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.28) EPS. As a group, sell-side analysts forecast that 10x Genomics will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on TXG. Citigroup lifted their price objective on shares of 10x Genomics from $18.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. Barclays lifted their price objective on shares of 10x Genomics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 14th. Stifel Nicolaus lifted their price objective on shares of 10x Genomics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. JPMorgan Chase & Co. lifted their price objective on shares of 10x Genomics from $17.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Finally, Bank of America lifted their price objective on shares of 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $23.17.

Check Out Our Latest Stock Analysis on TXG

Hedge Funds Weigh In On 10x Genomics

Hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. purchased a new position in shares of 10x Genomics during the fourth quarter worth approximately $38,000. Larson Financial Group LLC grew its position in shares of 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock worth $39,000 after acquiring an additional 1,470 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of 10x Genomics during the first quarter worth approximately $50,000. Van ECK Associates Corp grew its position in shares of 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after acquiring an additional 1,695 shares during the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new position in shares of 10x Genomics during the third quarter worth approximately $56,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

About 10x Genomics

(Get Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.